CAPRICOR THERAPEUTICS

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program

19 окт 2023 16:01:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society

10 окт 2023 09:00:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces $23 Million Registered Direct Offering

29 сен 2023 07:35:51 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

29 сен 2023 07:30:58 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

06 сен 2023 09:00:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

07 авг 2023 16:05:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7

02 авг 2023 16:01:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors

13 июл 2023 08:30:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

30 июн 2023 09:25:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

13 июн 2023 09:15:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

07 июн 2023 09:15:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

11 май 2023 16:01:01 Источник Nasdaq GlobeNewswire

Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11

04 май 2023 09:00:01 Источник Nasdaq GlobeNewswire

Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform

27 апр 2023 09:00:01 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

23 мар 2023 09:25:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

15 мар 2023 16:01:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15

08 мар 2023 09:00:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award

02 мар 2023 09:15:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan

16 фев 2023 09:25:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients

25 янв 2023 08:00:00 Источник Nasdaq GlobeNewswire